FDA Approves Calquence for Adults with Chronic Lymphocytic Leukemia
Print this page 21 November 2019 — AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The US approval was granted under the FDA’s Real-Time Oncology Review and newly established Project Orbis programmes. The approval is based on positive… Read More »